The US Food and Drug Administration has approved a new medication from biotech company AbbVie that treats adults with a type of lung cancer who have received previous treatment.
Reuters reports that the treatment, branded as Emrelis, belongs to a class of drugs known as antibody-drug conjugates, which act as “guided missiles” to target only cancer cells while sparing healthy cells, unlike conventional chemotherapy.
Emrelis was approved for a type of non-squamous non-small cell lung cancer (NSCLC), for which patients were previously treated with other drugs but where the disease still spread to other parts of the body.
These patients also showed an excess of c-Met protein, which is known to trigger tumour development and resistance to certain therapies.
According to the National Institutes of Health, about 25%-37% of patients with this type of lung cancer exhibit high c-Met protein over-expression.
NSCLC is the most common type of lung cancer in the United States, with roughly 197 000 cases a year.
The FDA’s accelerated approval was based on a mid-stage trial of 84 patients, where the drug showed an overall response rate of 35%. It is currently being evaluated in a late-stage trial.
Other treatment options for NSCLC include Merck’s blockbuster Keytruda and AstraZeneca’s Tagrisso, which belong to different classes of drugs.
Reuters article – US FDA approves AbbVie's drug for a type of lung cancer (Open access)
See more from MedicalBrief archives:
Lung cancer increasing among non-smokers, WHO warns
FDA approves Merck’s Ketruda — first new treatment for bladder cancer in 20 years
FDA approves chemo-free treatment for lung cancer